Resource Library
-
Global strategic preparedness and response plan launched by WHO to contain mpox outbreak
The World Health Organization (WHO) today launched a global Strategic Preparedness and Response Plan to stop outbreaks of human-to-human transmission of mpox through coordinated global, regional, and national efforts. This follows the declaration of a public health emergency of international concern by the WHO Director-General on 14 August 2025.
-
Learn about Mpox and Safer Sex
These downloadable fact sheets from the CDC answer common questions about safer sex, social gatherings, and mpox.
-
Mpox Resources from Greater Than
Demetre Daskalakis, MD, MPH, Acting Director of the National Center for Immunization and Respiratory Diseases at the CDC, provides the latest on mpox in this FAQ series from KFF and CDC.
-
U.S. Mpox Wastewater Data
Communities can monitor the presence of mpox virus in wastewater samples. Data from samples can provide an early warning of mpox activity and spread in communities. This dashboard from the CDC displays the latest sample data.
-
Tecovirimat (TPOXX) for Treatment of Mpox
To help meet domestic and international mpox response goals, CDC is urging clinicians to let patients with mpox know that oral tecovirimat is available through STOMP and encourage them to enroll. Providers should inform patients about STOMP so they can consider enrolling in the study.
-
Guidance for Tecovirimat (TPOXX)
Tecovirimat (TPOXX) and Guidance for Tecovirimat Use pages are now live.
-
U.S. Mpox Case Trends Reported to CDC
This dashboard displays trends of mpox cases reported to CDC during the 2022 outbreak by date. As of May 1, 2024, U.S. mpox case trends data will be updated the first week of every month.
-
Mpox Information for Health Departments
This resource page from the CDC provides examples and best practices for slowing the spread of mpox.
-
Case Definitions for Use in the Mpox Response
These case definitions from the CDC enable public health officials to classify and count mpox cases consistently across reporting jurisdictions.
-
NIH: Report on lower dose of mpox vaccine
Study highlights need for defined markers of mpox immunity to inform public health use.
-
NIH: Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen
Study highlights need for defined markers of mpox immunity to inform public health use.
-
Mpox FAQs for Clinicians
This fact sheet for clinicians provides information on identifying, controlling, and preventing mpox.
Main Menu
Additional Resources
© Copyright 2025 National Coalition for LGBTQ Health. All rights reserved. | Privacy Policy | Site Map